Resistance of some leukemic blasts to lysis by lymphokine activated killer (LAK) cells
- 24 April 1988
- journal article
- research article
- Published by Wiley in European Journal of Haematology
- Vol. 40 (4) , 362-367
- https://doi.org/10.1111/j.1600-0609.1988.tb00192.x
Abstract
Peripheral blood mononuclear cells (PBMC) from healthy donors and AML patients in remission were stimulated with phytohemagglutinin (PHA) and recombinant interleukin-2 (IL-2). These stimulated cells (lymphokine activated killer (LAK) cells) showed increased DNA synthesis as measured by 3H-Thymidine uptake. A synergistic effect of PHA and IL-2 was found. LAK cells'' ability to kill acute myeloid leukemia (AML) blasts was investigated by the 51Cr release assay. LAK cells showed a cytotoxicity (over 10% specific 51Cr release) against 9/12 leukemic blasts, even at effector/target (E/T) ratios as low as 5:1. However, on average only 22.2% (SD 11.8) and 36.5% (SD 12.5) 51Cr release were obtained in 4- and 18-hour cytotoxicity assays, respectively, at an E/T ratio of 20:1. Leukemic blasts in 3/12 AML cases and normal PBMC were entirely resistant to lysis, even at an E/T ratio of 80:1. Susceptibility to lysis was not correlated to peanut-agglutinin receptor expression. LAK cells were more cytotoxic towards the K-562 cell line (natural killer activity) than unstimulated PBMC.Keywords
This publication has 13 references indexed in Scilit:
- Induction of proliferation in vitro of resting human natural killer cells: IL 2 induces into cell cycle most peripheral blood NK cells, but only a minor subset of low density T cells.The Journal of Immunology, 1986
- Interleukin 2 (IL 2) up-regulates its own receptor on a subset of human unprimed peripheral blood lymphocytes and triggers their proliferation.The Journal of Immunology, 1986
- IL 2 alone is mitogenic only for Tac-positive lymphocytes in human peripheral blood.The Journal of Immunology, 1986
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- Tumor-associated antigens--an overview.Journal of Clinical Oncology, 1985
- Evidence of a dynamic role of the target cell membrane during the early stages of the natural killer cell lethal hit.The Journal of Immunology, 1984
- Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cellsThe Journal of Experimental Medicine, 1983
- Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.The Journal of Experimental Medicine, 1982
- T Cell Growth Factor: Parameters of Production and a Quantitative Microassay for ActivityThe Journal of Immunology, 1978
- In vitro „education”︁ on autologous human sarcoma generates non‐specific killer cellsInternational Journal of Cancer, 1975